Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Roche
James Chih-Hsin Yang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; Genentech; InnoPharmax; Lilly; Merck Serono; Novartis; Pfizer; Roche; Takeda
Honoraria - Abbott Laboratories; AstraZeneca; Bayer; Boehringer Ingelheim; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Dong-Wan Kim
Consultant or Advisory Role - Novartis
Wu-Chou Su
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Johan F. Vansteenkiste
No relevant relationships to disclose
Li Zhang
Consultant or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche
Research Funding - AstraZeneca; Lilly; Roche
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche
Bin Peng
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ying Gong
Employment or Leadership Position - Novartis
Sylvia Zhao
No relevant relationships to disclose
Taro Amagasaki
Employment or Leadership Position - Novartis
Mikhail Akimov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Daniel Shao-Weng Tan
Honoraria - Bayer; Novartis
Research Funding - Novartis